This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Jan 29, 2026
•
8 min read
🧬 Eikon Therapeutics targets $274M IPO for four clinical-stage oncology candidates, Halozyme Therapeutics acquires Surf Bio for up to $400M to expand subcutaneous drug delivery portfolio, Cellares raises $257M Series D for cell therapy manufacturing platform expansion, Eli Lilly + Seamless Therapeutics partner on hearing loss gene editing platform worth over $1.12B, Antheia raises $24M Series C second close - biosynthetic drug ingredient manufacturing, Tenpoint Therapeutics receives FDA approval for YUVEZZI (carbachol and brimonidine tartrate) combination eye drop treating presbyopia
Jan 28, 2026
9 min read
🧬 TRexBio raises $50M Series B extension for testing eczema drug TRB-061, Boehringer Ingelheim + Simcere Pharmaceutical partner on IBD bispecific antibody SIM0709 for up to $1.26B total, Roche's CT-388 achieves 22.5% weight loss in Ph2 obesity trial - advancing to Ph3 development, Baseline Therapeutics launches to test GLP-1 drug BT-001 for alcohol use disorder - challenging Eli Lilly, EU and India agree to sweeping free trade pact eliminating 11% tariff on pharmaceutical exports, FDA lifts clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase III trial for ATTR gene editing treatment
Jan 27, 2026
🧬 Sarepta Therapeutics' Elevidys gene therapy shows sustained benefits three years post-treatment in Ph3 Duchenne muscular dystrophy trial, Recipharm debuts new Bengaluru facility for beta-lactam drugs to meet tougher FDA contamination standards, 1stBio Therapeutics raises $22M Series D for HPK1 inhibitor clinical development, Fortitude Biomedicines launches with $13M seed to combine molecular glues with ADCs for next-generation cancer and autoimmune therapies, HanchorBio + WuXi Biologics partner on strategic collaboration for bi- and multi-functional fusion protein development, GSK's Arexvy receives European approval expansion for respiratory syncytial virus prevention in all adults 18 and older
Jan 26, 2026
🧬 Novo Nordisk's oral Wegovy shows very strong launch with 18,410 weekly prescriptions - surpassing other GLP-1s, ST Pharm secures $56M API manufacturing contract with undisclosed US biotech for oligonucleotide treatment, NICE reverses decision to recommend NHS funding for Pfizer's Talzenna with Xtandi for advanced prostate cancer, US House of Representatives passes $1.2T spending bill that could restart FDA's rare pediatric disease priority voucher program, GSK's Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) wins China approval for uncontrolled asthma treatment
Jan 23, 2026
🧬 Samsung Biologics becomes first Korean biopharma to surpass 2 trillion won ($1.36B) profit threshold in 2025, Sandoz eyes $322B biosimilar opportunity as 50+ biologics lose patent protection in golden decade ahead, global pharma manufacturing output surged 9.1% in 2025 due to US tariff threat front-loading activities, Corxel Pharmaceuticals raises $287M Series D1 for obesity pill development and testing, BioMarin veterans launch Mendra with $82M Series A to use AI for rare disease drug development, Corcept Therapeutics' relacorilant shows Ph3 overall survival benefit in platinum-resistant ovarian cancer, Bristol Myers Squibb + Janux Therapeutics partner on tumor-activated cancer drugs, $50M upfront, $850M total deal value
Jan 22, 2026
🧬 J&J targets $100B revenue for 2026, overcoming Stelara patent cliff with oncology growth, Insilico Medicine + Hygtia Therapeutics split rights for preclinical NLRP3 inhibitor - $10M upfront + $56M milestones, Otsuka gains EU approval for Dawnzera (donidalorsen) targeting prekallikrein for hereditary angioedema prevention following Ph3 results, Infinitopes raises $35.1M seed total for oesophageal cancer vaccine trial preparation, Bristol Myers Squibb + Microsoft partner on AI-powered lung cancer detection network, FDA launches PreCheck pilot program to streamline US drug manufacturing facility approval process starting February 1
Jan 21, 2026
🧬 GSK acquires RAPT Therapeutics for $2.2B - targeting food allergy market with ozureprubart antibody, Roche doubles Genentech's North Carolina facility investment to $2B targeting obesity treatments by 2029, Exciva raises $59M Series B for neuropsychiatric treatments + Alzheimer's agitation therapy, Moderna and Merck & Co.'s intismeran autogene plus Keytruda maintains 49% risk reduction in advanced melanoma Ph2 study, Pfizer sell ViiV Healthcare stake to Shionogi in deal worth $2.1 billion
Jan 20, 2026
6 min read
🧬 Sharp Services invests over €20 million ($23.2M) to expand European injectables packaging capacity amid strong market demand, Cytotheryx raises $60M Series A to develop cell therapy treatments for liver disease, Nxera Pharma reports positive Ph3 results for Quviviq (daridorexant) targeting orexin receptors in insomnia patients, Syngene International + Bristol Myers Squibb extend research collaboration through 2035 covering discovery to commercialization, Astellas Pharma's zolbetuximab receives Scottish Medicines Consortium approval for CLDN18.2-positive gastric cancer treatment
Jan 19, 2026
7 min read
🧬 Novo Nordisk's oral Wegovy shows strong early prescription uptake - outpacing rival Eli Lilly's Zepbound launch, AgomAb Therapeutics files $100M US IPO - ALK5 inhibitors for inflammatory diseases, ImmunityBio reports promising Ph1 results for CD19 CAR-NK cell therapy in Waldenström macroglobulinemia, AbelZeta + AstraZeneca expand GPC3 CAR-T therapy partnership with $630M China rights acquisition, Sobi's Aspaveli (pegcetacoplan) receives EU approval for C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis
Jan 16, 2026
🧬 Novo Nordisk Foundation commits $856M funding for Danish life science incubator BioInnovation Institute, Sanofi reportedly prepares renewed takeover bid for Ocular Therapeutix after rejecting $16-per-share offer, Oxford Biomedica confirms takeover talks with private equity group EQT after rejecting previous low offers, BD invests $110M to expand Nebraska syringe production amid rising GLP-1 and biologics demand, Ocugen's OCU410 gene therapy shows 46% lesion growth reduction in Ph2 trial for geographic atrophy, BMS Immunai collaborate on AI-powered immune system analysis using AMICA-OS platform (terms undisclosed), Sanofi's Myqorzo (aficamten) and Redemplo (plozasiran) win China approval for obstructive hypertrophic cardiomyopathy and familial chylomicronaemia syndrome
Jan 15, 2026
🧬 Novo Nordisk refocuses core business on diabetes and obesity - pulling back from unrelated indications, Eli Lilly expects second-quarter 2026 FDA decision on orforglipron obesity pill with priority voucher review, Sino Biopharmaceutical to acquire Hygieia Biomedical for $172M to expand siRNA chronic disease pipeline, Servier launches Servier Ventures with €200M ($232.8M) fund for oncology/neurology biotechs, Caldera Therapeutics launches with $112.5M funding and dual-targeting inflammatory bowel disease drug from China's Qyuns, Johnson & Johnson's Tecvayli (teclistamab) shows Ph3 success targeting BCMA in relapsed multiple myeloma patients, Jazz Pharmaceuticals sells priority review voucher from Modeyso approval for $200 million
Jan 14, 2026
10 min read
🧬 AbbVie commits $100B US R&D investment over 10 years - wins tariff and pricing exemptions, AstraZeneca acquires Modella AI to integrate multimodal foundation models into its oncology R&D operations, Proxima raises $80M seed for AI-powered proximity-based therapeutics for undruggable targets, Illumina + AstraZeneca + Merck & Co. + Eli Lilly partner on Billion Cell Atlas for AI drug discovery, Nuclera extends Series C to $87M for antibody engineering platform development, ImmunityBio's ANKTIVA (nogapendekin alfa inbakicept) shows positive Ph2/Ph3 results in non-small cell lung cancer, Novartis + Zonsen PepLib Biotech partner on peptide-based radiopharmaceutical asset for $50M upfront plus milestones, Sentynl Therapeutics and Fortress Biotech receive FDA approval for Zycubo targeting ATP7A protein for Menkes disease
